Strategic Partnerships Mabtech has recently formed CRO partnerships with Redoxis and Labcorp in 2026, indicating a strong appetite for collaboration with contract research organizations to expand reach and service offerings.

North America Presence In addition to its Stockholm headquarters, Mabtech operates a sales office in Cincinnati and engages with global distributors, signaling a distributed sales model with opportunities to leverage North American channels for instrument and kit sales.

New Product Platforms The launch of EYRAplex Flex, a customizable multiplex kit format, creates a near-term opportunity to upsell or bundle with Mabtech’s antibodies, kits, and instruments to researchers seeking tailored panels.

Executive Growth Appointment of a Chief Commercial Officer in 2026 suggests a renewed focus on commercial strategy, sales enablement, and market expansion, aligning with targeted outreach to life science buyers.

NAFTA and Global Expansion Partnerships with major players like MilliporeSigma and Sai Life Sciences indicate a push into North American and global markets, presenting cross-sell opportunities for existing customers and distributors seeking broader assay solutions.